RxDoctor Payments Data

Anita Elliott

Family · Americus, GANPI 1932510757

Payments from drug & device makers

$3,801in general payments, 2019–2025

Across 211 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$324
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$205
  • Ironwood Pharmaceuticals, Inc$198
  • Ardelyx, Inc.$177
  • Takeda Pharmaceuticals U.S.A., Inc.$174
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,76299%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,801 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$34,187
Medicare patients
291
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab37$1,032,892
CreonLipase/Protease/Amylase168$498,961
LinzessLinaclotide199$125,660
ZenpepLipase/Protease/Amylase28$49,155
Sucralfate175$21,374
Dexlansoprazole DrDexlansoprazole57$12,898
TrulancePlecanatide17$9,081
Entecavir11$6,440
Mesalamine ErMesalamine29$4,010
Budesonide EcBudesonide11$3,661
ClenpiqSod Picosulf/Mag Ox/Citric Ac20$3,443
ErythromycinErythromycin Base13$3,134
Ondansetron OdtOndansetron464$2,374
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl119$1,953
Esomeprazole Magnesium36$1,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$324$1,032,89237 claims
AbbVieCreon, Linzess$1,580$624,621367 claims
Aimmune Therapeutics, Inc.Zenpep$162$49,15528 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$205$9,08117 claims
Ferring Pharmaceuticals Inc.Clenpiq$62$3,44320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Americus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →